Skip to main content
Hematology and Oncology
ALL Specialities
ALL Specialities
/
Hematology and Oncology
Blood & Cancer Podcast
CME
Diseases & Conditions
Nonmalignant Hematologic Disorders
Anemia
Bleeding Disorders
Thrombosis
Breast Cancer
CNS/Brain Cancer
Gastrointestinal Cancer
Genitourinary Cancer
Renal Cell Carcinoma
Gynecologic Cancer
Head & Neck/Thyroid Cancers
Leukemia, Myelodysplasia, Transplantation
ALL
AML
Cellular Therapy
CLL
CML
Myelodysplastic Syndrome
Transplantation
Lung Cancer
Lymphoma & Plasma Cell Disorders
B Cell Lymphoma
Follicular Lymphoma
Hodgkin Lymphoma
Mantle Cell Lymphoma
Multiple Myeloma
Non-Hodgkin Lymphoma
T Cell Lymphomas
Melanoma
Nonmelanoma Skin Cancer
Sarcoma and GIST
COVID-19 Updates
Conference Coverage
Conference Coverage
T-cell lymphoma therapies on the horizon
Publish date:
February 9, 2018
EXPERT ANALYSIS FROM TCLF 2018
hematologynews@frontlinemedcom.com
Pages
« first
1
2
Recommended Reading
Severe psoriasis upped lymphoma risk in large cohort study
MDedge Hematology and Oncology
Pretransplantation mogamulizumab for ATLL raises risk of GVHD
MDedge Hematology and Oncology
‘Meaningful’ antitumor activity with lenalidomide monotherapy in ATL
MDedge Hematology and Oncology
Brentuximab vedotin beat methotrexate, bexarotene in cutaneous T-cell lymphoma
MDedge Hematology and Oncology
Neuropathic pain puts cancer survivors out of work
MDedge Hematology and Oncology
Phase III trial: VZV protects auto-HCT patients
MDedge Hematology and Oncology
Study shows childhood IBD increased cancer risk in adulthood
MDedge Hematology and Oncology
FDA approves brentuximab vedotin for primary cutaneous anaplastic large cell lymphoma
MDedge Hematology and Oncology
MAVORIC: Mogamulizumab tops vorinostat in pretreated CTCL
MDedge Hematology and Oncology
Clinical Endpoints in PTCL: The Road Less Traveled
MDedge Hematology and Oncology
T Cell Lymphomas
Aggressive Lymphomas
Lymphoma & Plasma Cell Disorders
All Specialties
